TOP - August 2016, Vol 9, No 3
The key arguments supporting the use of combination therapy with checkpoint blockade immunotherapies as the standard of care for treating metastatic melanoma arise from the combination’s high disease control rates; rapid deep responses; improved response rates; longer progression-free survival (PFS); and good estimated overall survival (OS), approaching 70% at 3 years, said Steven J. O’Day, MD, Professor of Medical Oncology, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, at the recent HemOnc Today Melanoma and Cutaneous Malignancies meeting. Read More ›
By Wayne Kuznar
An updated survivorship guideline from the National Comprehensive Cancer Network (NCCN) includes an extensive revision on addressing sexual function in cancer survivors. Read More ›
Physicians need to advocate for molecular profiling, according to Howard “Skip” Burris III, MD. Read More ›
Approval of First Liquid Biopsy to Detect EGFR Mutations in Lung Cancer Can Improve Patient Outcomes
The first liquid biopsy used to detect gene mutations that are associated with non–small-cell lung cancer (NSCLC) was approved by the US Food and Drug Administration (FDA). Read More ›
Own-occupation disability insurance is often a pharmacist’s best line of defense when protecting his or her income from a disabling event. Read More ›
By Wayne Kuznar
The investigational oral androgen receptor drug ODM-201 has significant antitumor activity with a favorable safety profile in men with metastatic castration-resistant prostate cancer, according to a pooled analysis of 2 early-phase clinical trials. Read More ›
Cigarette smoking is associated with a wide variety of adverse health effects. Read More ›
There is an urgent unmet need for more effective therapies in pancreatic cancer. Read More ›
Page 2 of 2
- 1
- 2